Anders Himmelmann has been on the European Society of Cardiology Clinical Round Table (ESC CRT) since 2013 and is representing the pharma industry in the CRT Nucleus.

Before joining the pharma industry Anders Himmelmann spent a long career in academic medicine, primarily focusing on preventive cardiology. He is qualification as a specialist in internal medicine, cardiology and clinical pharmacology, and associate professor of internal medicine at the University of Gothenburg. Anders Himmelmann has been president of the Swedish society of hypertension and is a former editor of the journal Blood Pressure.

In 2007 Anders Himmelmann joined AstraZeneca, where has been working in Patient Safety, Early Clinical Development, and late-stage development. He currently holds the position as Global Clinical Head for the antiplatelet agent ticagrelor and the factor Xa inhibitor reversal agent andexanet alpha, in BioPharmaceuticals R&D Late-stage Development, Cardiovascular, Renal and Metabolic therapeutic area.